drugset / Trial / NCT05134337

Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants

NCT05134337

Phase 1 Completed 27 enrolled Loxo Oncology, Inc.
Non-randomizedSequentialOpen-labelBasic science

Summary

The main purpose of this study is to learn about how itraconazole and rifampin affect LOXO-305 in healthy participants. Participation could last about 8 weeks.

Timeline

Start
2020-02-12
Primary completion
2020-10-30
Completion
2020-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg Oral
Subject Pirtobrutinib Other / unclassified 200 mg Oral
Subject Rifampin Small molecule 600 mg Oral

Indications

No indication recorded.